Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 1181 to 1190 of 2588 total matches.
Brigatinib (Alunbrig) for Non-Small Cell Lung Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Apr 23, 2018 (Issue 1545)
inhibits ALK and other receptor
tyrosine kinases.
Table 1. Pharmacology
Class ALK/ROS1 tyrosine kinase ...
The FDA has approved brigatinib (Alunbrig – Takeda),
an oral tyrosine kinase inhibitor, for treatment of
patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC)
who have progressed on or are intolerant to crizotinib
(Xalkori). Translocations of the ALK gene are found in
about 5% of lung cancers; they occur predominantly
in nonsmokers with adenocarcinoma. Brigatinib is the
third tyrosine kinase inhibitor to be approved for this
indication; ceritinib (Zykadia) and alectinib (Alecensa)
were approved earlier, and subsequently were...
Prevention and Treatment of Monkeypox
The Medical Letter on Drugs and Therapeutics • Sep 05, 2022 (Issue 1658)
the US.1 Updated information
about the current outbreak is available from the CDC.2
MONKEYPOX ― Monkeypox ...
An outbreak of monkeypox has recently spread around
the globe and across the US. Updated information
about the current outbreak is available from the CDC.
Zuranolone (Zurzuvae) – An Oral Drug for Postpartum Depression
The Medical Letter on Drugs and Therapeutics • Dec 25, 2023 (Issue 1692)
in 2019.1
Key Points: Zuranolone (Zurzuvae)
Description: A GABAA receptor modulator and an analog ...
The FDA has approved the oral GABAA receptor
modulator zuranolone (Zurzuvae – Sage Therapeutics/Biogen) for treatment of postpartum depression
(PPD). Zuranolone is the second drug to be approved
for this indication; brexanolone (Zulresso), another
GABAA receptor modulator, was approved for IV
treatment of PPD in 2019.
Med Lett Drugs Ther. 2023 Dec 25;65(1692):201-3 doi:10.58347/tml.2023.1692a | Show Introduction Hide Introduction
Formoterol (Perforomist) for COPD
The Medical Letter on Drugs and Therapeutics • Nov 19, 2007 (Issue 1274)
)-enantiomer of formoterol, was
approved earlier this year for the same indication.
1
Drug class Long-acting ...
Formoterol fumarate (Perforomist - Dey), a long-acting beta2-agonist, was recently approved by the FDA as an inhalation solution for nebulization for maintenance treatment of bronchoconstriction associated with chronic obstructive pulmonary disease (COPD). Arformoterol (Brovana), the (R, R)-enantiomer of formoterol, was approved earlier this year for the same indication.
When a Statin Fails
The Medical Letter on Drugs and Therapeutics • Jul 27, 2009 (Issue 1317)
(1.8 mmol/L) a reasonable goal for
patients at very high risk.
LDL-C TARGETS — A meta-analysis of 58 ...
The National Cholesterol Education Program recommends that LDL-C be lowered to less than 100 mg/dL (2.6 mmol/L) and considers a value <70 mg/dL (1.8 mmol/L) a reasonable goal for patients at very high risk.
Primary Prevention of Ulcers in Patients Taking Aspirin or NSAIDs
The Medical Letter on Drugs and Therapeutics • Mar 08, 2010 (Issue 1333)
have an especially high risk.
1
Drugs that have been tried for prevention of ulcers in patients taking NSAIDs ...
Aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) are common causes of peptic ulcer disease. Patients infected with Helicobacter pylori who take aspirin or another NSAID have an especially high risk. Drugs that have been tried for prevention of ulcers in patients taking NSAIDs including H2-receptor antagonists, proton pump inhibitors (PPIs), aluminum- or magnesium-containing antacids, the prostaglandin misoprostol (Cytotec, and others), and antibiotics to eradicate H. pylori.Click here to view the free full...
Pitavastatin (Livalo) - The Seventh Statin
The Medical Letter on Drugs and Therapeutics • Jul 26, 2010 (Issue 1343)
Daily Dosage
1
LDL Cholesterol Cost
2
Atorvastatin – Lipitor (Pfizer) 10, 20, 40, 80 mg ...
The FDA has approved the marketing of pitavastatin (Livalo – Kowa), an HMG-CoA reductase inhibitor
(“statin”), for treatment of primary hyperlipidemia or mixed dyslipidemia. It has been available in Japan
since 2003. All of the statins now available in the US are listed in the table on page 58.
Intraurethral Alprostadil for Impotence
The Medical Letter on Drugs and Therapeutics • Mar 28, 1997 (Issue 997)
). It is marketed in a sterile foil
pouch containing a pellet 1.4 mm in diameter and 3 or 6 mm long within the stem ...
The prostaglandin alprostadil injected into the corpus cavernosum (Caverject - Upjohn) can produce an erection in some men with erectile dysfunction (Medical Letter, 37:83, 1995). Now a pellet (microsuppository) formulation has become available for intraurethral administration of alprostadil (MUSE [Medicated Urethral System for Erection] - Vivus). It is marketed in a sterile foil pouch containing a pellet 1.4 mm in diameter and 3 or 6 mm long within the stem of a hollow applicator, which is inserted 3 cm deep into the urethra. Pressing a button pushes the pellet into the urethra.
In Brief: Airborne
The Medical Letter on Drugs and Therapeutics • Jan 03, 2005 (Issue 1199)
The Medical Letter
®
On Drugs and Therapeutics
1
FORWARDING OR COPYING IS A VIOLATION OF U.S ...
Patients may be asking about Airborne, a dietary supplement that is being heavily promoted for prevention and treatment of colds. It contains 7 herbal extracts, 3 vitamins, 2 amino acids, selenium, zinc and many other ingredients. Airborne Jr is available for children. There are some concerns. First, there is no conclusive evidence that this product or any of its ingredients prevents colds or shortens their duration. Second, the adult tablet contains 1 g of vitamin C, and the directions for use advise taking 1 tablet at the first sign of a cold and repeating the dose every 3 hours as...
A Responsive Neurostimulator Device (RNS System) for Epilepsy
The Medical Letter on Drugs and Therapeutics • Jul 21, 2014 (Issue 1447)
as monotherapy
before considering use of two drugs at the
same time.1
About 30-40% of patients with epilepsy ...
The FDA has approved the use of a responsive
neurostimulator device (RNS System – NeuroPace)
for adjunctive treatment of adults with partial-onset
seizures that are not controlled with ≥2 antiepileptic
drugs and who have frequent and disabling seizures
and no more than 2 epileptogenic foci.